Building on the positive outcomes and approval of small-molecule inhibitors targeting FGFR and IDH oncogenic signaling in CCA, several other therapeutic strategies focusing on different oncogenic pathways are currently being explored for advanced-stage CCA. This evidence concerns the gene IDH2 and cholangiocarcinoma.